Focus Partners Wealth
AMRX icon

Focus Partners Wealth’s Amneal Pharmaceuticals AMRX Stock Holding History

Focus Partners Wealth’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,203
Closed -$242K – 2653
2025
Q3 		$242K Buy
+4,203
New +$37.7K ﹤0.01% 1953

Other funds holding AMRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Focus Partners Wealth's AMRX Position: Q4 2025 in Review

Focus Partners Wealth sold out of Amneal Pharmaceuticals (AMRX) in Q4 2025, closing a stake of 4,203 shares — an estimated $242K sold.

Focus Partners Wealth first reported a position in AMRX in Q3 2025 and held it in 1 quarter. The position peaked at $242K in Q3 2025. 277 funds tracked by Wall St. Rank hold AMRX as of Q4 2025.

  • Focus Partners Wealth reported no remaining Amneal Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Focus Partners Wealth sold 4,203 Amneal Pharmaceuticals shares in Q4 2025, an estimated $242K.
  • Focus Partners Wealth first reported a position in Amneal Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Focus Partners Wealth's Amneal Pharmaceuticals position peaked at $242K in Q3 2025.
  • 277 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q4 2025.

Based on Focus Partners Wealth's 13F filing for Q4 2025, filed 13 Feb 2026.